Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Research Triangle Park, Nc, Us
- Industry
- Biotechnology
- Website
- http://www.evecxia.com
- HQ
- Research Triangle Park, NC
Evecxia Therapeutics, Inc. Questions
Evecxia Therapeutics, Inc.'s website is http://www.evecxia.com
Evecxia Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/evecxia-therapeutics-inc
Evecxia Therapeutics, Inc. has
5 employees.
View email and phone details for 5
employees at Evecxia Therapeutics, Inc..
Evecxia Therapeutics, Inc.'s industry is
Biotechnology
Evecxia Therapeutics, Inc.'s top competitors are
Immvention Therapeutix, Inc.,
Psilera,
Ribometrix Inc.,
Tenax Therapeutics,
Accession Therapeutics Limited,
Grid Therapeutics,
Madera Therapeutics,
Tavros Therapeutics,
Incyclix Bio,
Pinetree Therapeutics Inc.
Evecxia Therapeutics, Inc.'s categories are Biotechnology
Evecxia Therapeutics, Inc.'s founding year is 2013
